This search looks for keywords in all of the website’s content. Search tips
Filter by
- Agenda(1916)
- Annex to CHMP highlights(367)
- Annual Report(94)
- Application withdrawal assessment report(276)
- Committee meeting report(882)
- COVID-19 vaccine safety update(71)
- Direct healthcare professional communication(122)
- EPAR - All authorised presentations(1980)
- EPAR - Amended Product Information(1)
- EPAR - Assessment report - Variation(2711)
- EPAR - Assessment report on maintenance of orphan designation - Initial authorisation(141)
- EPAR - Assessment report on maintenance of orphan designation - Post-authorisation(42)
- EPAR - Conditions imposed on member states for safe and effective use(112)
- EPAR - Overview(1976)
- EPAR - Paediatric investigation plan compliance statement(89)
- EPAR - Procedural steps taken and scientific information after authorisation(1887)
- EPAR - Procedural steps taken before authorisation(484)
- EPAR - Product Information(1976)
- EPAR - Public assessment report(1551)
- EPAR - Risk-management-plan summary(1144)
- EPAR - Scientific conclusion(1358)
- EPAR - Scientific Discussion(504)
- EPAR - Scientific Discussion - Variation(188)
- EPAR - Steps taken after authorisation when a cutoff date has been used(170)
- Herbal - Call for data(293)
- Herbal - Herbal monograph(118)
- Herbal - HMPC assessment report(476)
- Herbal - HMPC opinion on a European Union herbal monograph(247)
- Herbal - List of references supporting the assessment report(462)
- Herbal - Overview of comments received during consultation(164)
- Herbal - Summary of assessment report for the public(120)
- Herbal – European Union herbal monograph(330)
- Herbal – European Union list entry(19)
- Leaflet(72)
- Maximum Residue Limits - Divergent opinion(2)
- Maximum Residue Limits - Opinion(88)
- Maximum Residue Limits - Report(804)
- Maximum Residue Limits - Summary of opinion(14)
- Medicine QA(456)
- Medicines under additional monitoring(24)
- Minutes(1250)
- Newsletter(299)
- Opinion outside EU - All presentations(14)
- Opinion outside EU - Assessment report - Variation(9)
- Opinion outside EU - Medicine questions and answers(1)
- Opinion outside EU - Procedural steps taken and scientific information after opinion(11)
- Opinion outside EU - Procedural steps taken before opinion(3)
- Opinion outside EU - Product information(15)
- Opinion outside EU - Public assessment report(12)
- Opinion outside EU - Risk-management-plan summary(11)
- Opinion outside EU - Scientific discussion(4)
- Opinion outside EU - Summary for the public(15)
- Opinion outside EU - Summary of opinion(3)
- Opinion outside EU - Summary of opinion - Initial authorisation(9)
- Opinion outside EU - Withdrawal assessment report(1)
- Orphan designation(2420)
- Orphan review(106)
- Other(4061)
- Overview of comments(330)
- Parallel distribution(1)
- Periodic safety update single assessment(2763)
- PIP - Notification of discontinuation of a paediatric development which is covered by an agreed PIP decision(109)
- PIP - Paediatric-investigation-plan summary(93)
- PIP decision(5491)
- Position statement(29)
- PRAC recommendation on signal(164)
- Presentation(5308)
- Press Release(1708)
- Procurement(73)
- Public Statement(485)
- Recommendation on medication errors(26)
- Recruitment(38)
- Referrals document(2782)
- Regulatory and procedural guideline(723)
- Report(1620)
- Scientific guideline(2465)
- Standard Operating Procedure - SOP(129)
- Summary of opinion(1223)
- Summary of opinion - Initial authorisation(1675)
- Supply shortage(58)
- Template or form(480)
- Withdrawal letter(290)
- Work Instruction - WIN(61)
- Work programme(151)
- Advanced therapies(1797)
- Antimicrobial resistance(270)
- Biologicals(147)
- Biosimilars(654)
- Brexit(121)
- Careers(6)
- Clinical trials(603)
- Compassionate use(16)
- Compliance and inspections(600)
- Corporate(116)
- COVID-19(898)
- Data on medicines(941)
- Early access(201)
- Fees(24)
- Generic and hybrid medicines(2186)
- Governance(708)
- Innovation(1164)
- Maximum residue limit(1002)
- Medication error(28)
- Medicines(47117)
- Medicines for use outside the EU(148)
- Medicine shortages(300)
- Mpox(39)
- Paediatrics(12261)
- Parallel distribution(15)
- Pharmacovigilance(9673)
- Procurement(132)
- Product information(6318)
- Quality of medicines(224)
- Rare diseases(8243)
- Referrals(3395)
- Regulatory and procedural guidance(3516)
- Research and development(494)
- Scientific advice(289)
- Scientific guidelines(1754)
- SME(259)
- Vaccines(1500)
- Veterinary limited markets(64)
Search results (84452)
Atazanavir Viatris (previously Atazanavir Mylan) : EPAR - All Authorised presentations
English (EN) (47.81 KB - PDF)
български (BG) (53.63 KB - PDF)
español (ES) (31.92 KB - PDF)
čeština (CS) (49.81 KB - PDF)
dansk (DA) (44.17 KB - PDF)
Deutsch (DE) (43.11 KB - PDF)
eesti keel (ET) (43.7 KB - PDF)
ελληνικά (EL) (44.02 KB - PDF)
français (FR) (15.25 KB - PDF)
hrvatski (HR) (71.34 KB - PDF)
íslenska (IS) (44.96 KB - PDF)
italiano (IT) (42.68 KB - PDF)
latviešu valoda (LV) (60.44 KB - PDF)
lietuvių kalba (LT) (63.63 KB - PDF)
magyar (HU) (62.61 KB - PDF)
Malti (MT) (34.96 KB - PDF)
Nederlands (NL) (44.65 KB - PDF)
norsk (NO) (35.61 KB - PDF)
polski (PL) (34.5 KB - PDF)
português (PT) (9.86 KB - PDF)
română (RO) (48.06 KB - PDF)
slovenčina (SK) (59.28 KB - PDF)
slovenščina (SL) (40.33 KB - PDF)
Suomi (FI) (54.37 KB - PDF)
svenska (SV) (35.22 KB - PDF)
Tecartus : EPAR - Risk-management-plan summary
English (EN) (13.82 MB - PDF)
Tecartus : EPAR - Product information
English (EN) (320.1 KB - PDF)
български (BG) (631.78 KB - PDF)
español (ES) (450.66 KB - PDF)
čeština (CS) (584.41 KB - PDF)
dansk (DA) (456.04 KB - PDF)
Deutsch (DE) (485.19 KB - PDF)
eesti keel (ET) (489.85 KB - PDF)
ελληνικά (EL) (755.77 KB - PDF)
français (FR) (466.95 KB - PDF)
hrvatski (HR) (540.73 KB - PDF)
íslenska (IS) (533.28 KB - PDF)
italiano (IT) (460.3 KB - PDF)
latviešu valoda (LV) (525.07 KB - PDF)
lietuvių kalba (LT) (563.02 KB - PDF)
magyar (HU) (602.67 KB - PDF)
Malti (MT) (621.72 KB - PDF)
Nederlands (NL) (456.4 KB - PDF)
norsk (NO) (454.99 KB - PDF)
polski (PL) (621.87 KB - PDF)
português (PT) (444.93 KB - PDF)
română (RO) (593.96 KB - PDF)
slovenčina (SK) (589.66 KB - PDF)
slovenščina (SL) (615.42 KB - PDF)
Suomi (FI) (465.56 KB - PDF)
svenska (SV) (444.85 KB - PDF)
Tecartus : EPAR - Procedural steps taken and scientific information after the authorisation
English (EN) (191.12 KB - PDF)
Baqsimi : EPAR - Product information
English (EN) (516.13 KB - PDF)
български (BG) (726.86 KB - PDF)
español (ES) (474.08 KB - PDF)
čeština (CS) (621.3 KB - PDF)
dansk (DA) (747.1 KB - PDF)
Deutsch (DE) (721.55 KB - PDF)
eesti keel (ET) (667.69 KB - PDF)
ελληνικά (EL) (742.35 KB - PDF)
français (FR) (657.24 KB - PDF)
hrvatski (HR) (590.3 KB - PDF)
íslenska (IS) (639.65 KB - PDF)
italiano (IT) (671.9 KB - PDF)
latviešu valoda (LV) (678.73 KB - PDF)
lietuvių kalba (LT) (604.46 KB - PDF)
magyar (HU) (652.65 KB - PDF)
Malti (MT) (641.43 KB - PDF)
Nederlands (NL) (581.16 KB - PDF)
norsk (NO) (604.7 KB - PDF)
polski (PL) (679.64 KB - PDF)
português (PT) (762.72 KB - PDF)
română (RO) (666.15 KB - PDF)
slovenčina (SK) (650.14 KB - PDF)
slovenščina (SL) (669.02 KB - PDF)
Suomi (FI) (645.43 KB - PDF)
svenska (SV) (607.65 KB - PDF)
The staff and experts of the European Medicines Agency (EMA) publish articles on the Agency's scientific activities in scientific publications, such as journals or textbooks.
Baqsimi : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (114.41 KB - PDF)